286 related articles for article (PubMed ID: 37335663)
1. Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review.
Rhyne C; Cohen JM; Seminerio MJ; Carr K; Krasenbaum LJ
Medicine (Baltimore); 2023 Jun; 102(23):e33874. PubMed ID: 37335663
[TBL] [Abstract][Full Text] [Related]
2. Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study.
Ito Y; Mitsufuji T; Okada M; Fujita S; Yokoyama R; Kawasaki H; Yamamoto T
Intern Med; 2023 Dec; 62(23):3455-3460. PubMed ID: 37062749
[TBL] [Abstract][Full Text] [Related]
3. Preventive Treatment of Migraine.
Lipton RB
Continuum (Minneap Minn); 2024 Apr; 30(2):364-378. PubMed ID: 38568488
[TBL] [Abstract][Full Text] [Related]
4. [Novel migraine treatment with CGRP-related monoclonal antibodies].
Shibata M
Rinsho Shinkeigaku; 2020 Oct; 60(10):668-676. PubMed ID: 32893246
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
6. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
Friedman DI; Cohen JM
Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
8. Unmet Needs in the Acute Treatment of Migraine.
Bentivegna E; Galastri S; Onan D; Martelletti P
Adv Ther; 2024 Jan; 41(1):1-13. PubMed ID: 37943442
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience.
Raffaelli B; Fitzek M; Overeem LH; Storch E; Terhart M; Reuter U
J Headache Pain; 2023 Feb; 24(1):16. PubMed ID: 36843007
[TBL] [Abstract][Full Text] [Related]
10. Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments.
Nissan GR; Kim R; Cohen JM; Seminerio MJ; Krasenbaum LJ; Carr K; Martin V
J Clin Med; 2022 Jul; 11(15):. PubMed ID: 35955976
[TBL] [Abstract][Full Text] [Related]
11. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
Curone M; Tullo V; Didier HA; Bussone G
Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
[TBL] [Abstract][Full Text] [Related]
12. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
13. CGRP and headache: a brief review.
Tepper SJ
Neurol Sci; 2019 May; 40(Suppl 1):99-105. PubMed ID: 30835001
[TBL] [Abstract][Full Text] [Related]
14. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice.
Tiseo C; Ornello R; Pistoia F; Sacco S
J Headache Pain; 2019 May; 20(1):49. PubMed ID: 31060490
[TBL] [Abstract][Full Text] [Related]
15. Galcanezumab for the prevention of migraine.
Frerichs LM; Friedman DI
Pain Manag; 2021 Mar; 11(2):101-112. PubMed ID: 33291980
[TBL] [Abstract][Full Text] [Related]
16. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
Sevivas H; Fresco P
Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
18. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
Caronna E; Gallardo VJ; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
J Headache Pain; 2021 Oct; 22(1):120. PubMed ID: 34620085
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
[TBL] [Abstract][Full Text] [Related]
20. Harris Poll Migraine Report Card: population-based examination of high-frequency headache/migraine and acute medication overuse.
Starling AJ; Cady R; Buse DC; Buzby M; Spinale C; Steinberg K; Lenaburg K; Kymes S
J Headache Pain; 2024 Feb; 25(1):26. PubMed ID: 38408888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
